Protein kinases such as the serine-and threonine-specific enzyme family protein kinase C (PKC) are essential elements in the transduction of cellular signals elicted by growth factors and hormones, and they play a pivotal role in the regulation of cell differentiation and proliferation (Nishizuka, 1992) . Not surprisingly therefore, they are prominent targets for the design of novel anti-cancer drugs. Pharmacological interference with PKC seems a logical therapeutic strategy because in certain experimental neoplasias altered PKC function or expression have been linked to malignant transformation (Cacace et al., 1993; Mischak et al., 1993) . Modulators of PKC activity are currently under clinical evaluation, and the results of two phase I trials of the PKC activator bryostatin 1 have recently been published (Phillip et al., 1993; Prendiville et al., 1993) . The dose-limiting toxicity of bryostatin 1 was myalgia, and in one of the trials the drug exhibited activity against malignant melanoma (Phillip et al., 1993) . Numerous inhibitors of PKC have been described, and most of them possess cytostatic and cytotoxic properties (Tamaoki and Nakano, 1990) . They may also be useful in therapy as synergistic enhancers of the antitumour activity of conventional cytotoxic anti-cancer drugs (Posada et al., 1989; Sato et al., 1990; Utz et al., 1994) and as inhibitors of tumour cell invasion (Schwartz et al., 1993) . Most of these molecules are only modestly selective inhibitors of PKC and affect a variety of kinases. For example, the microbial product staurosporine is a potent, but non-selective, kinase inhibitor. Two analogues with higher specificity for PKC, 41251 , have shown significant antitumour activity in vivo (Meyer et al., 1989; Akinaga et al., 1991) . Both of these drugs are in preparation for phase 1 clinical evaluation as anti-cancer drugs, the former in Japan and the United States and the latter in Europe. In the work described here the hypothesis was tested that inhibition of PKC is related to inhibition of cell growth. Several PKC inhibitors of diverse chemical structure ( Figure 1) were assessed for their ability to interfere with PKC activity and proliferation in two human-derived carcinoma cell lines. Furthermore, their effect on the growth of cells which had lost PKC activity via enzyme down-regulation was studied.
Paradoxically staurosporine is not only an effective inhibitor of PKC but it also shares certain properties with activators of this enzyme (Dlugosz and Yuspa, 1991) . In most cell types PKC is contained predominantly in the cytosol and its activation engenders alterations in the subcellular localisation of the enzyme. Activator-induced translocation of PKC is thought to position the enzyme in close proximity to its physiologically important-substrates. For example, in human A549 lung and MCF-7 breast carcinoma cells the tumour promoter 12-0-tetradecanoyl phorbol-13-acetate (TPA) and the experimental anti-tumour agent bryostatin 1 provoke the rapid redistribution of PKC from the cytosol to the particulate and nuclear fractions (Issandou et al., 1988; (Bradshaw et al., 1992) . In view of these findings we wished to elucidate whether the effect on the subcellular localisation of PKC is a general feature of PKC inhibitors or a specific property of staurosporine. To answer this question the effect of a series of diverse kinase inhibitors on the localisation of the PKC isoenzymes contained in A549 cells was investigated. The agents tested include H-7, its positional isomer H-71 and the staurosporine analogues UCN-01, CGP 41251, RO 31-8220 and GF 109203X, which are thought to inhibit PKC at the catalytic domain, and the regulatory domain inhibitors calphostin C and miltefosine. The overall aim of the study was to increase the understanding of the way in which different PKC inhibitors interact with tumour cells and to explore the role which this class of agent may play in cancer therapy.
Materials and methods
Drugs and reagents RO 31-8220, CGP 41251, NPC 15437, trimethylsphingosine, UCN-01, miltefosine and bryostatin 1 were provided by Roche Research Centre (Welwyn Garden City, UK), Ciba Geigy (Basle, Switzerland), Nova Pharmaceutical (Baltimore, MD, USA), Biomembranes Institute (Seattle, WA, USA), Kyowa Hakko Kogyo (Tokyo, Japan), Asta Pharma (Frankfurt, Germany) and Cancer Research Institute, Arizona State University (Tempe, AR, USA) respectively. Calphostin C, H-7 and GF 109203X were acquired from Calbiochem-Novabiochem (Nottingham, UK). Other chemicals and reagents including staurosporine, H-7I and TPA were purchased from Sigma (Poole, UK) and 3H-labelled thymidine ([3H]Tdr) from Amersham International (Amersham, UK). Stock solutions of NPC 15437, trimethylsphingosine and H-7 were prepared in water, those of other kinase inhibitors, TPA and bryostatin in dimethyl sulphoxide (DMSO), and stored at -20C. The final concentration of DMSO in the medium did not exceed 0.3%, which on its own did not affect cell growth. A monoclonal antibody against PKC-a was purchased from Tissue Culture Services Biologicals (Botolph Claydon, UK). The polyclonal antibody against PKC-4 and its antigenic peptide was acquired from Gibco BRL (Paisley, UK) and a polyclonal antibody against PKC-e was provided by Dr P Parker (ICRF Laboratories, London, UK).
Cell growth Human A549 lung and MCF-7 breast carcinoma cells were obtained from the European Collection of Animal Cell Cultures (Salisbury, UK). Cells (passage number 10-30) were cultured in an atmosphere of 5% carbon dioxide, the former in Ham's F-12 medium with penicillin/streptomycin, the latter in minimum essential medium (Eagle's modification) with additional pyruvate (1 mM) and non-essential amino acids. Both media were supplemented with 10% FCS (Imperial Laboratories Europe, Andover, UK, and Gibco) and glutamine (2 mM). Cells were subcultured routinely twice weekly to maintain logarithmic growth. For cell proliferation studies cells were seeded at a density of 1.3 x 104 cm-2 and incubated with 3 ml of medium including agents, which was replenished at intervals of 48 h (A549) or 72 h (MCF-7). Following incubation for 4 days (A549) or 6 days (MCF-7) with drugs, cell number was assessed using a Coulter Counter Model ZM. In order to achieve PKC depletion, cells seeded at 1-2 x 105 per well (3.5 cm diameter) were incubated for 24 h with bryostatin 1 (1 tLM). Under these conditions growth inhibition caused by bryostatin 1 is negligible Stanwell et al., 1994) . Bryostatin was removed by extensive washing of the cells followed by a 2 h recovery period. In previous work using the A549 cell line this washing procedure has been shown to eliminate bryostatin-mediated effects. The cells were then incubated for a further 24 h with staurosporine, RO 31-8220, UCN-01 or H-7. In some experiments cells were incubated with inhibitor for 48 rather than 24 h, in this case bryostation was not removed and left in the incubate. After removal of agents inhibition of DNA synthesis was evaluated by measurement of [3H]Tdr incorporation into cells as described previously . Radioactivity was counted using a Packard 1500 Tricarb scintillation counter.
Measurement of PKC activity Cytosol was prepared as described previously , and aliquots were placed with kinase inhibitor at appropriate concentrations in microplate wells. PKC activity was measured via the incorporation of the y-phosphate moiety of [32P]ATP into a PKC-specific peptide using a kit from Amersham International. The value obtained with this kit is the sum of activities of phospholipid-dependent, Ca2+-dependent and -independent PKC isoenzymes which are activated by phorbol esters.
Preparation of cellular fractions and Western blot analysis Cytosolic, particulate (which contains membranes, cytoskeleton and cell organelles) and nuclear fractions of cells were obtained essentially as described before (Greif et al., 1992) with some modifications (Stanwell et al., 1994) . Protein content of the fractions was measured by the Bradford assay (Bradford, 1976) . Western blot analysis was performed as described previously (Stanwell et al., 1994) . The amount of protein loaded per lane was 20 tg for detection of cPKC-oc and 30 lg for nPKC-e. Detection was by enhanced chemiluminescence generated by oxidation of luminol in the presence of hydrogen peroxide using an ECL kit from Amersham International. Immunoreactivity was quantitated using Molecular Dynamics Computing Densitometer, and the values shown in Figures 4 and 5 are expressed as a percentage of the sum of immunoreactive protein in all three fractions. The significance of differences in band intensity was evaluated by Student's t-test.
Results
Relationship between inhibition of PKC and inhibition of cell growth Nine PKC inhibitors, staurosporine (Tamaoki et al., 1986) , UCN-01 (Takahashi et al., 1987) , RO 31-8220 (Davis et al., 1992 ), CGP 41251 (Meyer et al., 1989 , GF 109203X (Toullec et al., 1991 ), calphostin C (Kobayashi et al., 1989 , miltefosine (Uberall et al., 1991) , NPC-15437 (Sullivan et al., 1991) and H-7 (Hidaka et al., 1984) (for structures see Figure  1 ), were investigated for their ability to inhibit cell growth and PKC activity isolated from the cytosol of two carcinoma cell lines. In the case of the A549 cells, two further agents, trimethylsphingosine (Endo et al., 1991) and H-71, a positional isomer of H-7, were included. Of these agents staurosporine and calphostin C inhibited growth most effectively in both cell types (Table I) for MCF-7 cells. These results suggest that the ability of these agents to arrest cell growth is not reflected by their capability to inhibit PKC. Nevertheless, this conclusion has to be interpreted with caution in view of differences in design between the two experiments, in that the effect of the compounds on proliferation was assessed in intact cells, whereas enzyme inhibition was measured in cytosolic extracts in vitro.
Growth arrest in PKC-depleted cells To define more precisely the role which PKC might play in growth arrest caused by these agents, their effect on cells with down-regulated PKC was investigated. The hypothesis tested in this experiment was that, if inhibition of PKC mediates growth arrest, then PKC-depleted cells should be less susceptible towards the cytostatic potential of these agents than PKC-proficient naive cells. Cells were exposed for 24h to bryostatin 1 at 1 riM, which caused the complete downregulation of conventional (c) PKC-o and novel (n) PKC-c as assessed by Western blot analysis (Stanwell et al., 1994 Table I ). This discrepancy is probably due to differences in procedures between the two experiments, particularly with regard to exposure time and seeding density. Cells responded similarly to GF 109203X, which, like RO 31-8220, is a PKC-specific bisindolylmaleimide analogue of staurosporine (Toullec et al., 1991) . Likewise, in parallel experiments PKC-depleted MCF-7 cells did not markedly differ from control MCF-7 cells in sensitivity towards kinase inhibitors (results not shown). In order to rule out the possibility that the incubation time was insufficient for the kinase inhibitors to exert maximal growth-inhibitory potency, the experiment was repeated and the cells were exposed to staurosporine or RO 31-8220 for 48 h rather than 24 h with bryostatin present in the incubate for the duration of the entire experiment. The IC50 values determined in these experiments are similar to those described above. Also, under these conditions the sensitivity of the PKC-depleted cells towards the growth-arresting potential of the kinase inhibitors was slightly increased compared with that of their PKCproficient counterparts (results not shown), analogous to the observation made in the 24 h exposure study. Effect of PKC inhibitors on cell growth and PKC localisadon C Courage et al H-7 or H7-I (both 0.5 mM) in the presence or absence of TPA (25 nM). Cellular fractions were prepared, and levels of PKC isoenzymes were determined by Western blot analysis using a monoclonal anti-PKC-o antibody and polyclonal antibodies against PKCs-e and -<. Our previous studies have shown that these three PKC isoenzymes are abundantly expressed in A549 cells (Stanwell et al., 1994) . Consistent with its ability to attenuate the TPA-mediated change in distribution of phorbol ester binding sites (Bradshaw et al., 1992) , staurosporine increased TPA-induced translocation of cPKC-c. Although the effect was not significant, as deduced from the densitometry readings, a definite trend was observed (P = 0.08) (Figure 4) . One other agent, UCN-01 at 1 JAM, behaved similarly. However, results with UCN-01 were inconsistent, as it augmented TPA in only three out of six blots. The staurosporine analogues CGP 41251, RO 31-8220 and GF 109203X, like calphostin C, miltefosine, H-7 and H-7I, failed to affect TPA-induced cPKC-a redistribution. None of the inhibitors changed TPAinduced relocalisation of nPKC-e. However, when staurosporine, UCN-01, RO 31-8220 and GF 109203X were incubated with cells on their own, they caused the redistribution of nPKC-s from the cytosol to the particulate and nuclear fractions ( Figure 5) . Staurosporine was the most potent translocating agent, with a slight effect observed at 1 and 10 nM (result not shown). For all four agents the effect was noticeable at 0.1 AM and strong at 1 JAM. Thus, except in the case of staurosporine, the concentrations required to elicit nPKC-c translocation were considerably greater than those which caused PKC inhibition (see Table I ). CGP 41251, calphostin C, miltefosine, H-7 or H7-I did not alter nPKC-c localisation. The intracellular distribution of the third PKC isoenzyme expressed in A549 cells, PKC-? (Stanwell et al., 1994), was not affected by any of the inhibitors.
Discussion
The finding that PKC inhibitors possess antiproliferative properties can be rationalised in terms of the fact that the enzyme is a pivotal regulator of cell growth and differentiation. Thus its inhibition is likely to cause interruption-of signal transduction pathways vital for cellular sur- vival. Nevertheless the experimental basis for the notion that inhibition of PKC activity is causally associated with ability to arrest growth has been tenuous, particularly in view of the fact that most so-called 'PKC inhibitors' possess only modest specificity for PKC, or none at all. Some evidence for such a link was provied by experiments on quercetin, staurosporine (Hofmann et al., 1988) and the alkyllysophospholipid BM 41440 (Grunicke et al., 1989) in 3T3 fibroblasts, even though these compounds are clearly promiscuous in their ability to inhibit kinases. In these cells the dose-effect relationship with regard to inhibition of PKC was found to be similar to the dose-response curves for depression of replication.
In the study presented above two separate experimental approaches were adopted, and the results do not support the notion that there is a mechanistic link between inhibition of Figure 2 probably mirrors gross differences between agents in their affinity for kinases in general, not only for PKC. Secondly, PKC-depleted cells were not less, but more, sensitive towards the growth-inhibitory effect of the kinase inhibitors compared with naive cells. If growth arrest caused by PKC inhibitors was indeed mediated by the interruption of signal transduction mechanisms operating via PKC one would expect proliferation of PKC-depleted cells to be less affected by these agents than that of PKC-proficient cells. This puzzling finding can perhaps be explained by the increased intracellular availability of kinase inhibitors enabling them to interact with other targets when PKC-o and -E are eliminated as binding sites. An alternative explanation relates to the fact that cellular targets of bryostatin 1 other than PKC have yet to be defined. Bryostatin might up-regulate certain kinases, which consequently can be more effectively inhibited in the presence of staurosporine or its analogues. It is now recognised that results obtained using agents such as bryostatin to down-regulate PKC have to be interpreted with prudence as the initial enzyme activation caused by them elicits numerous intracellular events before loss of PKC. Irrespective of the mechanism involved, our results hint at the possibility that the combination of kinase inhibitors with PKC-down-regulating agents such as bryostatin 1 may be of therapeutic benefit.
The cells used in this study express cPKC-a, nPKC-c and PKC-4 (Stanwell et al., 1994) . Of these enzymes cPKC-ac and nPKC-e were efficiently down-regulated by exposure to bryostatin, whereas the 4-isoenzyme is resistant to downregulation by this agent (Stanwell et al., 1994) . Therefore one could surmise that it is inhibition of PKC-; which might mediate the growth arrest caused by these agents irrespective of cellular PKC-a and -a levels. This hypothesis seems especially compelling in the light of the recent suggestion that PKC-4 plays a critical role in the control of mitogenic signalinduced proliferative cascades downstream of p2lr'a (Berra et al., 1993) . However, PKC-g is unlikely to be involved with the mechanism of growth inhibition as it seems to be virtually unaffected by analogues of staurosporine, at least in intact cells . It is also noteworthy that the effect of PKC down-regulation was essentially equal in the two cell lines regardless of the fact that relative levels of PKC-x and -e differ considerably between them (Stanwell et al., 1994) . As PKC is apparently not a primary mediator of the cytostatic properties of kinase inhibitors in A549 and MCF-7 cells, other kinases may be involved. One candidate is p34c&2 kinase, which is inhibited by staurosporine almost as strongly as PKC (Gadbois et al., 1992) . Overall, the observations described above cast doubt on the notion that PKC-selective inhibitors are superior in their antineoplastic properties to inhibitors of other kinases, an inference which should be borne in mind in the search for novel kinase inhibitors as anti-cancer drugs.
Staurosporine possesses a puzzling mixture of phorbol ester agonistic and antagonistic properties (Dlugosz and Yuspa, 1991) . It inhibits PKC enzyme activity potently, but also causes the subcellular translocation of nPKCs (Kiley et al., 1992) and augments TPA-induced redistribution of phorbol ester binding sites (Bradshaw et al., 1992 One of the aims of this study was to explore any relationship between structure and activity among staurosporine and four of its analogues with respect to their effects on cell growth and on PKC. In both cell types the order of growthinhibitory potency was staurosporine > UCN-01 > CGP 41251 >RO 31 8220 >GF 109203X. The order of their enzyme-inhibitory efficacy was RO 31-8220 = GF 109203X = UCN-01 > staurosporine = CGP 41251 with PKC obtained from A549 cells, and staurosporine = UCN-01 = GF 109203X > RO 31 8220 = CGP 41251 with PKC from MCF-7 cells. Intriguingly, CGP 41251 is a strong inhibitor of both cell growth and PKC activity, but incapable of eliciting nPKC-e translocation. In contrast, UCN-01 interfered strongly with growth and PKC activity and also altered nPKC-c localisation, whereas RO 31-8220 and GF 109203X are efficacious enzyme inhibitors and caused nPKC-c redistribution, yet they are rather poor inhibitors of cell growth. These differences in potency allow tentative interpretation of the complicated structure-activity relationships which govern the abilities of these compounds to affect PKC and cell growth. The indolocarbazole staurosporine inhibited PKC and growth with high potency. These properties are not adversely affected by the addition of a hydroxy group at carbon 7 of the aglycone part (UCN-01), or of a benzoyl moiety on the nitrogen in position 4' of the glycone part of the staurosporine molecule (CGP 41251) (see Figure 1 ). Yet the presence of N-benzoyl abolishes its nPKC-s translocatory efficacy. The change from the indolocarbazole to the bisindolylmaleimide structural skeleton, that is from staurosporine to RO 31-8220 and GF 109203X, retains the ability to inhibit PKC and to translocate nPKC-e, but diminishes strongly the growth-inhibitory potential of the molecule.
In conclusion, this study suggests that PKC does not play a direct role in the mechanisms by which PKC inhibitors arrest the growth of A549 and MCF-7 carcinoma cells. Furthermore, it seems that for a PKC inhibitor to affect subcellular enzyme localisation it has to be an analogue of staurosporine which possesses a high affinity for PKC. Further studies on these compounds will help to understand the mechanism by which they interfere with cell growth and perhaps point to other constituents of signal-transducing kinase cascades as suitable targets in the development of novel drugs.
Abbreviations: ICs,o 50% inhibitory concentration; cPKC, conventional (Ca2"-dependent) protein kinase C; nPKC, novel (Ca2"-independent) protein kinase C; [3H]Tdr, [methyl-
[3H]thymidine; TPA., 12-0-tetradecanoyl phorbor-13-acetate.
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